JW Shinyak Corporation

KQ:067290 Korea Pharmaceuticals
Market Cap
$57.04 Million
₩83.51 Billion KRW
Market Cap Rank
#22010 Global
#1085 in Korea
Share Price
₩2010.00
Change (1 day)
-0.25%
52-Week Range
₩1319.00 - ₩2480.00
All Time High
₩10766.98
Categories
Companies in Korea Pharmaceuticals
About

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more

JW Shinyak Corporation (067290) - Net Assets

Latest net assets as of September 2025: ₩38.73 Billion KRW

Based on the latest financial reports, JW Shinyak Corporation (067290) has net assets worth ₩38.73 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩64.75 Billion) and total liabilities (₩26.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩38.73 Billion
% of Total Assets 59.82%
Annual Growth Rate -0.13%
5-Year Change -52.44%
10-Year Change -33.13%
Growth Volatility 46.4

JW Shinyak Corporation - Net Assets Trend (2007–2024)

This chart illustrates how JW Shinyak Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for JW Shinyak Corporation (2007–2024)

The table below shows the annual net assets of JW Shinyak Corporation from 2007 to 2024.

Year Net Assets Change
2024-12-31 ₩26.90 Billion +63.58%
2023-12-31 ₩16.44 Billion -70.62%
2022-12-31 ₩55.97 Billion +0.96%
2021-12-31 ₩55.44 Billion -1.97%
2020-12-31 ₩56.56 Billion -14.50%
2019-12-31 ₩66.14 Billion +97.51%
2018-12-31 ₩33.49 Billion -9.07%
2017-12-31 ₩36.83 Billion -4.58%
2016-12-31 ₩38.60 Billion -4.05%
2015-12-31 ₩40.23 Billion -5.25%
2014-12-31 ₩42.46 Billion -5.53%
2013-12-31 ₩44.94 Billion -8.48%
2012-12-31 ₩49.11 Billion -7.00%
2011-12-31 ₩52.81 Billion +119.80%
2008-12-31 ₩24.02 Billion -12.59%
2007-12-31 ₩27.49 Billion --

Equity Component Analysis

This analysis shows how different components contribute to JW Shinyak Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4710.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock ₩25.42 Billion 94.50%
Other Components ₩68.81 Billion 255.80%
Total Equity ₩26.90 Billion 100.00%

JW Shinyak Corporation Competitors by Market Cap

The table below lists competitors of JW Shinyak Corporation ranked by their market capitalization.

Company Market Cap
Conrad Industries Inc
PINK:CNRD
 		$42.36 Million
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
 		$42.36 Million
Garuda Construction & Engineering
NSE:GARUDA
 		$42.37 Million
BIT Computer Co. Ltd
KQ:032850
 		$42.37 Million
Triple i Logistics Public Company Limited
BK:III
 		$42.36 Million
Taeyang Metal
KO:004100
 		$42.34 Million
BICO Group AB (publ)
PINK:BCCOY
 		$42.34 Million
Cots Technology Co Ltd
KQ:448710
 		$42.32 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in JW Shinyak Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 16,770,420,100 to 26,899,920,840, a change of 10,129,500,740 (60.4%).
  • Net income of 5,081,548,870 contributed positively to equity growth.
  • Dividend payments of 1,610,000,000 reduced retained earnings.
  • Share repurchases of 18,770,500 reduced equity.
  • Other factors increased equity by 6,676,722,370.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩5.08 Billion +18.89%
Dividends Paid ₩1.61 Billion -5.99%
Share Repurchases ₩18.77 Million -0.07%
Other Changes ₩6.68 Billion +24.82%
Total Change ₩- 60.40%

Book Value vs Market Value Analysis

This analysis compares JW Shinyak Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.98x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 2.23x to 3.98x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩902.16 ₩2010.00 x
2017-12-31 ₩826.28 ₩2010.00 x
2018-12-31 ₩731.10 ₩2010.00 x
2019-12-31 ₩1443.98 ₩2010.00 x
2020-12-31 ₩1229.25 ₩2010.00 x
2021-12-31 ₩1147.84 ₩2010.00 x
2022-12-31 ₩1216.95 ₩2010.00 x
2023-12-31 ₩330.77 ₩2010.00 x
2024-12-31 ₩505.38 ₩2010.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently JW Shinyak Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 18.89%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.46%
  • • Asset Turnover: 1.48x
  • • Equity Multiplier: 2.34x
  • Recent ROE (18.89%) is above the historical average (-22.71%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -1.24% -0.72% 0.57x 2.98x ₩-4.79 Billion
2015 0.64% 0.33% 0.60x 3.17x ₩-3.77 Billion
2016 -1.25% -0.58% 0.58x 3.72x ₩-4.34 Billion
2017 -16.50% -7.91% 0.62x 3.35x ₩-9.76 Billion
2018 -22.42% -8.18% 0.84x 3.26x ₩-10.86 Billion
2019 2.18% 1.41% 0.75x 2.07x ₩-5.17 Billion
2020 -11.40% -6.21% 1.08x 1.70x ₩-12.10 Billion
2021 1.59% 0.88% 1.10x 1.66x ₩-4.66 Billion
2022 2.50% 1.36% 1.09x 1.68x ₩-4.20 Billion
2023 -222.76% -35.84% 1.59x 3.91x ₩-39.03 Billion
2024 18.89% 5.46% 1.48x 2.34x ₩2.39 Billion

Industry Comparison

This section compares JW Shinyak Corporation's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $96,196,506,488
  • Average return on equity (ROE) among peers: -9.52%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
JW Shinyak Corporation (067290) ₩38.73 Billion -1.24% 0.67x $42.36 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Sam-A Pharm. Co. Ltd (009300) $148.92 Billion 6.63% 0.09x $21.27 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $257.20 Billion 4.73% 0.21x $50.06 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million